ES2109914T3 - Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer. - Google Patents
Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer.Info
- Publication number
- ES2109914T3 ES2109914T3 ES88100233T ES88100233T ES2109914T3 ES 2109914 T3 ES2109914 T3 ES 2109914T3 ES 88100233 T ES88100233 T ES 88100233T ES 88100233 T ES88100233 T ES 88100233T ES 2109914 T3 ES2109914 T3 ES 2109914T3
- Authority
- ES
- Spain
- Prior art keywords
- hormones
- disease
- levels
- senile dementia
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 8
- 239000005556 hormone Substances 0.000 title abstract 7
- 229940088597 hormone Drugs 0.000 title abstract 7
- 206010039966 Senile dementia Diseases 0.000 title abstract 4
- 230000001195 anabolic effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 3
- 108010051696 Growth Hormone Proteins 0.000 abstract 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 206010008027 Cerebellar atrophy Diseases 0.000 abstract 1
- 206010008096 Cerebral atrophy Diseases 0.000 abstract 1
- 208000032862 Clinical Deterioration Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 239000000854 Human Growth Hormone Substances 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- -1 cathecoline Chemical compound 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 201000006517 essential tremor Diseases 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
UN METODO DE TRATAR ENFERMEDADES HUMANAS DE MALES DEL SISTEMA NERVIOSO CENTRAL, TAL COMO EL MAL DE ALZHEIMER, ATROFIA CEREBRAL, MAL DE PARKISON, DEMENCIA SENUL, TEMBLOR SENIL, ESCLEROSIS MULTIPLE, ACCIDENTES CEREBRO VASCULARES Y ATROFIA CEREBERAL, ASI TAMBIEN COMO MALES DONDE LA DEMENCIA ESTA PRESENTE. EL TRATAMIENTO CONSISTE EN INCLUIR DENTRO DEL FLUJO SANGUINEO DEL PACIENTE AL MENOS UNO DE DEL GRUPO QUE CONSISTE EN: HORMONAS SEXUALES Y HORMONAS ANABOLICAS (HGH, NCG, HORMONO TROFOBOSTICA). MUSELATO ERGOBIAL, DOPAMINE, CATECOLINE, SEROTONINA, ANFETAMINA, DEBEN SER USADAS EN CONJUNCION CON LA HORMONA, ASI TAMBIEN COMO UN VASODILATADOR Y ANTI - INFLAMATORIO NO ESTEROIDE. LA HORMONA DE CRECIMIENTO DEBE TAMBIEN SER USADA EN ESOS PACIENTES EN ESTADOS AVANZADOS DE LA ENFERMEDAD, O EN ESOS PACIENTES DONDE HA SIDO DETERMINADO QUE UN BAJO NIVEL DE LA HORMONA DE CRECIMIENTO ES PRESENTE, LA DETERIORIZACION CLINICA QUE NO HA SIDO CORREGIDA POR OTRAS HORMONAS. UN METODO DE DIAGNOSTICAR EL MAL DE ALZHEIMER, LA DEMENCIA SENIL, POR LA DETERMINACION DE LOS NIVELES DE LAS HORMONAS SOMATOTROPINA (HORMONA DE CRECIMIENTO HUMANO) Y SOMATOMEDINA - C (IGFI) DESPUES DE LA ADMINISTRACION DEL TEST ESTIMULANTE AROONSAKUL - AKEN. MUESTRAS DE SANGRE SUERO SON TOMADAS CADA TREINTA MINUTOS POR UN PERIODO DE DOS HORAS DESPUES DE LA ADMINISTRACION DE L - DOPA, Y LAS MUESTRAS SON TESTADAS POR LOS NIVELES DE ESAS HORMONAS. ESTOS NIVELES SON ENTONCES COMPARABLES CONTRA LOS NIVEWLES PARA SUJETOS NORMALES EN EL GRUPO DE EDAD DE ENTRE CINCUENTA Y SESNTA AÑOS. SI LOS NIVELES DEL PACIENTE QUE ES DIAGNOSTICADO CAEN POR DEBAJO DEL METODO ESTADISTICO POR ERROR, ENTONCES UN DIAGNOSTICO DE MAL DE ALZHEIMER ES INDICADO QUE ES EQUIVALENTE A SEVERA DEFICIENCIA HGH, POCO SEVERA Y MODERADA, DEFICIENCIA HGH QUE INDICAN DEMENCIA SENIL EN ESTADO TEMPRANO Y RECIENTE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP88100233A EP0324037B1 (en) | 1988-01-11 | 1988-01-11 | Use of anabolic hormones for the manufacture of a medicament for the treatment of Alzheimer's disease and senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2109914T3 true ES2109914T3 (es) | 1998-02-01 |
Family
ID=8198634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES88100233T Expired - Lifetime ES2109914T3 (es) | 1988-01-11 | 1988-01-11 | Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0324037B1 (es) |
| AT (1) | ATE157546T1 (es) |
| DE (1) | DE3856017T2 (es) |
| ES (1) | ES2109914T3 (es) |
| GR (1) | GR3025576T3 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149786A (en) * | 1989-10-12 | 1992-09-22 | Chiron Corporation | Dopamine releasing protein and antibody |
| IT9041720A1 (it) * | 1990-10-26 | 1992-04-26 | Fidia Spa | Metodo per la diagnosi del parkinson idiopatico |
| WO1994022469A1 (en) * | 1993-04-02 | 1994-10-13 | Ohio University | Enhancement of learning and/or memory by a human somatotropin |
| SE9804064D0 (sv) | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| ATE353653T1 (de) * | 2003-07-29 | 2007-03-15 | Acme Srl | Verwendung von stanozolol zur herstellung von entzündungshemmenden und antidegenerativen arzneimitteln |
-
1988
- 1988-01-11 ES ES88100233T patent/ES2109914T3/es not_active Expired - Lifetime
- 1988-01-11 AT AT88100233T patent/ATE157546T1/de not_active IP Right Cessation
- 1988-01-11 EP EP88100233A patent/EP0324037B1/en not_active Expired - Lifetime
- 1988-01-11 DE DE3856017T patent/DE3856017T2/de not_active Expired - Fee Related
-
1997
- 1997-12-03 GR GR970403226T patent/GR3025576T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3856017D1 (de) | 1997-10-09 |
| DE3856017T2 (de) | 1998-04-23 |
| ATE157546T1 (de) | 1997-09-15 |
| EP0324037B1 (en) | 1997-09-03 |
| EP0324037A1 (en) | 1989-07-19 |
| GR3025576T3 (en) | 1998-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Volder et al. | Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration | |
| EP0276723B1 (de) | Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins | |
| Gruen et al. | Growth hormone responses to hypoglycemia in postmenopausal depressed women | |
| Hunter et al. | Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication | |
| Gibb et al. | Pathological report of four patients presenting with cranial dystonias | |
| Sachar et al. | Human growth hormone response to levodopa: Relation to menopause, depression, and plasma dopa concentration | |
| Sunohara et al. | A new syndrome of anosmia, ichthyosis, hypogonadism, and various neurological manifestations with deficiency of steroid sulfatase and arylsulfatase C | |
| US4902680A (en) | Treating central nervous system diseases | |
| Oren et al. | Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder | |
| Linkowski et al. | The 24-hour profile of plasma prolactin in men with major endogenous depressive illness | |
| Takahashi et al. | Antidepressant effect of thyrotropin‐releasing hormone (TRH) and the plasma thyrotropin levels in depression | |
| Gadoth et al. | Episodic hormone secretion during sleep in Kleine-Levin syndrome: evidence for hypothalamic dysfunction | |
| Morimoto et al. | Epileptic seizures precipitated by constant light, movement in daily life, and hot water immersion | |
| Juckel et al. | Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment | |
| De Reuck et al. | A double‐blind study of neurotropin in patients with acute ischemic stroke | |
| ALBIN et al. | ABNORMAL HYPOTHALAMIC‐PITUITARY FUNCTION IN POLYOSTOTIC FIBROUS DYSPLASIA | |
| ES2109914T3 (es) | Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer. | |
| US20250049883A1 (en) | Animal, fungal and marine sources of cgp and increased cgp concentration for disease management and for treatment of non-neurological and/or neurological conditions | |
| US4898856A (en) | Method for treating central nervous system diseases | |
| Kirch et al. | Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients | |
| US4898857A (en) | Treating control nervous system diseases | |
| US5017470A (en) | Method of diagnosing alzheimer's disease and senile dementia | |
| Mathew et al. | Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients | |
| Bierich et al. | New observations on midline defects: coincidence of anophthalmos, microphthalmos and cryptophthalmos with hypothalamic disorders | |
| JP2850128B2 (ja) | 老化度測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 324037 Country of ref document: ES |